摘要
蛋白错折叠的靶向通路以及这些通路中间体的毒性的治疗方案仍处于早期,除了在晚期试验中没能得到能够产生疗效较好的单克隆抗体。临床上的失败为进一步开发治疗神经退行性疾病的药物提供了经验。更有效的药物可以通过追求以下两种策略来实现。首先,错误折叠蛋白质聚集体的构象靶向,而不是包括单体亚基的较少特异性结合,其大大超过毒性靶标。第二,由于神经退行性疾病通常包括不止一种潜在的蛋白质病理通路,通过形状的聚集体的通用靶向也可能是候选药物的关键特征。使用小分子方法或用抗体片段还没有实现将这些关键特征与高亲和力结合一起结合到可行的药物候选物中。到目前为止开发的单克隆抗体不是广泛地通过构象识别起作用。使用GAIM(通用淀粉样蛋白相互作用基序)是一种新的方法,其并入了针对多个蛋白质组装体的高亲和力构象识别,以及识别沿寡聚物和纤维之间的错误折叠路径的组装阵列。 GAIM-Ig融合物NPT088,接近临床测试。
关键词: 病理生理学,,细胞繁殖,传染性海绵状脑病
Current Alzheimer Research
Title:Conformation as the Therapeutic Target for Neurodegenerative Diseases
Volume: 14 Issue: 4
关键词: 病理生理学,,细胞繁殖,传染性海绵状脑病
摘要: Therapeutic strategies that target pathways of protein misfolding and the toxicity of intermediates along these pathways are mainly at discovery and early development stages, with the exception of monoclonal antibodies that have mainly failed to produce convincing clinical benefits in late stage trials. The clinical failures represent potentially critical lessons for future neurodegenerative disease drug development. More effective drugs may be achieved by pursuing the following two strategies. First, conformational targeting of aggregates of misfolded proteins, rather than less specific binding that includes monomer subunits, which vastly outnumber the toxic targets. Second, since neurodegenerative diseases frequently include more than one potential protein pathology, generic targeting of aggregates by shape might also be a crucial feature of a drug candidate. Incorporating both of these critical features into a viable drug candidate along with high affinity binding has not been achieved with small molecule approaches or with antibody fragments. Monoclonal antibodies developed so far are not broadly acting through conformational recognition. Using GAIM (General Amyloid Interaction Motif) represents a novel approach that incorporates high affinity conformational recognition for multiple protein assemblies, as well as recognition of an array of assemblies along the misfolding pathway between oligomers and fibers. A GAIM-Ig fusion, NPT088, is nearing clinical testing.
Export Options
About this article
Cite this article as:
Conformation as the Therapeutic Target for Neurodegenerative Diseases, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205014666170116152622
DOI https://dx.doi.org/10.2174/1567205014666170116152622 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Cellular Toxicity of Mesoporous Silica Nanoparticle in SHSY5Y and BMMNCs Cell
Pharmaceutical Nanotechnology Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Innovative Anthocyanin/Anthocyanidin Formulation Protects SK-N-SH Cells Against the Amyloid-β Peptide-Induced Toxicity: Relevance to Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Sphingolipids as Emerging Drug Targets: Therapeutic Applications of Ceramide Analogs
Drug Design Reviews - Online (Discontinued) Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design General Aspects of Metal Toxicity
Current Medicinal Chemistry Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Signal Transduction via Cannabinoid Receptors
CNS & Neurological Disorders - Drug Targets Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design